#### TITLE PAGE

1

- 2 **Title:** Atherosclerotic Cardiovascular Disease and Health-Related Quality of Life Among Adults
- 3 in the United States: National Health Interview Survey 2013-2017
- 4 **Authors:** Kobina K. Hagan, MBChB, MPH; <sup>1</sup> Zulqarnain Javed, PhD, MBBS, MPH; <sup>1</sup> Isaac
- 5 Acquah, MBChB, MPH; Tamer Yahya, MD; Javier Valero-Elizondo, MD, MPH; Adnan A.
- 6 Hyder, MD, MPH, PhD;<sup>3</sup> Elias Mossiolas, MD, PhD;<sup>4,5</sup> Shubham Lahan, MD;<sup>1</sup> Miguel Cainzos-
- 7 Achirica, MD, MPH, PhD;<sup>1,2</sup> & Khurram Nasir, MD, MPH, MSc<sup>1,2</sup>
- 8 Affiliations:
- 9 Center for Health Data Sciences and Analytics, Houston Methodist, Houston, TX, U.S.A.
- 10 <sup>2</sup> Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston
- 11 Methodist DeBakey Heart & Vascular Center, Houston, TX, U.S.A.
- 12 <sup>3</sup> Center on Commercial Determinants of Health, Milken Institute School of Public Health, The
- 13 George Washington University, Washington, DC, U.S.A.
- <sup>4</sup> Department of Health Policy, London School of Economics and Political Sciences, U.K.
- <sup>5</sup> Centre for Health Policy, Imperial College London, U.K.
- 16 **Running Title:** ASCVD & Health-related Quality of Life
- 17 Corresponding Author:
- 18 Khurram Nasir, MD, MPH, MSc.
- 19 Division of Cardiovascular Prevention and Wellness, Department of Cardiology
- 20 Houston Methodist DeBakey Heart & Vascular Center
- 21 6550 Fannin St Suite 1801, Houston, TX 77030
- E-mail: knasir@houstonmethodist.org. Phone: (443) 413-6350. Twitter: @khurramn1
- 23 **Word Count:** Abstract (249). Full text (4,958).
- Tables: 2. Figures: 1. Supplemental Tables: I-IV.

### **ABSTRACT**

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

**Background:** A brief health-related quality of life (HRQoL) tool with construct validity for atherosclerotic cardiovascular disease (ASCVD) may facilitate integration into healthcare delivery. We examined ASCVD-related changes in the Health and Activity Limitation Index (HALex), a generic HRQoL measure comprising perceived health and activity limitation. **Methods:** Using data of 155,130 respondents of the National Health Interview Survey 2013-2017, we evaluated HALex scores by ASCVD (angina, heart attack, and stroke). Lower HALex scores reflected worse HRQoL and a 0.03 change was regarded as the threshold for clinical significance. Multivariable two-part models were used to assess HALex changes (β, 95%CI) associated with ASCVD overall and in sex, age, and race/ethnicity groups. **Results**: Overall, participants with ASCVD – 6.8%, representing 15.7 million adults – had lower HALex scores (0.67) than those without ASCVD (0.87). Females, age  $\geq$  65 years, and non-Hispanic Blacks had the lowest HALex scores. Overall, ASCVD was associated with a substantial decrement in HALex (-0.10, [-0.10, -0.09]). Interactions between ASCVD and sex, and race/ethnicity were both significant (p < 0.001). ASCVD-associated decrement in HALex was clinically greater in: females (-0.11, [-0.12, -0.10]) than in males (-0.08, [-0.09, -0.07]); and non-Hispanic Black (-0.13, [-0.15, -0.1]) than in non-Hispanic White (-0.09, [-0.10, -0.08]). Though ASCVD impact on HALex was greater in age 18-64 years (-0.09, [-0.10, -0.08]), it was not statistically different from the elderly (-0.06, [-0.07, -0.06]). Conclusions: ASCVD was consistently associated with lower HRQoL, as measured by HALex, across major demographics. HALex presents a feasible HRQoL tool to implement in healthcare.

- 46 **Keywords**
- 47 ASCVD; atherosclerotic cardiovascular disease; quality of life; Health and Activity Limitation
- 48 Index; HALex

Non-standar	on-standard Abbreviations and Acronyms				
ASCVD	atherosclerotic cardiovascular disease				
COPD	chronic obstructive pulmonary disease				
GED	General Educational Development				
HALex	Health and Activity Limitation Index				
HRQoL	health-related quality of life				
NHIS	National Health Interview Survey				

57 PROM patient-reported outcome measures

58 SE standard error

# FULL TEXT

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

INTRODUCTION

Atherosclerotic cardiovascular disease (ASCVD) is associated with a high burden of debilitating symptoms and emotional stress related to decompensation and recurrent events, and invasive management. With a plenitude of life-extending treatments and a shift in healthcare quality assessment to value-based care, there is a growing call for the routine use of patient-reported outcome measures (PROMs) like health-related quality of life (HRQoL) in the clinic beyond trials (1). HRQoL not only summarizes wellbeing from a patient's perspective, but is associated with subsequent cardiovascular events, mortality, and the patterns of healthcare utilization and expenditure (2,3). However, the implementation of HRQoL assessment in clinical workflow is limited by factors including the lengthy surveys in commonly used research tools such as the 36-item Short Form Survey (or its shortened version, Short Form 12) and other utility-based tools (4). On the other hand, the Health and Activity Limitation Index (HALex) is a generic HRQoL measure that combines two items – perceived health and physical functioning – into a global score for wellbeing (5). It is mathematically derived and is not subject to the variations other HROoL tools with community rated utility scores have owing to differing measuring techniques and geographic variation (6–8). With a low administrative burden, HALex may be useful in the clinic for assessing the impact of chronic conditions including ASCVD. In this cross-sectional analysis, we described the differences in HROoL associated with the presence of ASCVD among U.S. adults using HALex. As a convenient and reliable alternative to more detailed tools, we expected ASCVD-related decrements in HALex in the total population

and within sex, age, and race/ethnicity groups.

#### **METHODS**

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

## Study design and sampling

This study used the 2013-2017 National Health Interview Survey (NHIS) data. The NHIS is an annual household interview survey of the United States (U.S.) civilian, non-institutionalized population sponsored by the National Center for Health Statistics and under the auspices of the Centers for Disease Control and Prevention (9). Interviews are conducted using a complex, multistage probability design to reflect changes in the distribution of the U.S. population and produce nationally representative estimates. The NHIS has four core components – Household Composition, Family, Sample Child, and the Sample Adult – which provide information on respondents' sociodemographic characteristics, health status and activity limitations, behavior indicators, and health care access and utilization. In addition, NHIS data are supplemented with survey weights to account for selection probabilities and non-response. Since NHIS data files are publicly available and de-identified, this study was exempt from Institutional Review Board review. We used respondents aged ≥18 years from the Family Core, Sample Adult Core, and Person files merged and pooled over five years (2013-2017). Since NHIS data files are publicly available and de-identified, this study was exempt from the purview of Houston Methodist's Institutional Review Board.

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Study variables Atherosclerotic Cardiovascular Disease Respondents who affirmed ever receiving a clinician diagnosis of "angina pectoris", "heart attack (or myocardial infarction)", "coronary heart disease", or "stroke" were classified as having ASCVD. Respondents with no information on their ASCVD status (1,052 [0.7%]) were excluded from the analysis. All other NHIS participants included in the analysis were considered to not have ASCVD. The Health and Activity Limitation Index HALex is based on two routinely assessed health indicators included in the NHIS: perceived health status and levels of physical activity limitation (5). Responses to perceived health status are subjective and include "excellent", "very good", "good", "fair", and "poor". The assessment of physical activity limitation is objective and the responses include: 1) not limited, 2) limited in other activities, 3) limited in major activity, 4) unable to perform a major activity, 5) unable to perform instrumental activities of daily living, and 6) unable to perform activities of daily living (personal care needs). The mathematical derivation of HALex has been described extensively (10). In brief, responses to the two items are combined in a matrix of 30 health states (**Appendix**). For persons alive, HALex scores range from 0.10 to 1.00 (11). Two outcomes were assessed – our primary outcome, mean HALex score, and a secondary binary outcome, poor HALex performance. We categorized patients with HALex scores less than 0.84 (i.e., 20<sup>th</sup> percentile of the study sample distribution) as having poor HALex (12). There are

no widely established cut-off values for HALex, but the threshold for a clinically relevant impact

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

is suggested to be 0.03 (13). We interpreted our results with this threshold. In sum, data of 155,130 participants with complete information on ASCVD and HALex, and non-zero HALex scores (i.e., alive) were used in this study. **Covariates** Other variables included in this study were age (linear) and age group (18-64 years and ≥65 years); sex (male and female); race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, non-Hispanic Asian, Hispanic, and Other); educational attainment (no high school diploma, high school diploma/GED equivalent, some college, and ≥ college degree); health insurance plan (uninsured, any private plan, Medicare, Medicaid, and other plans); household income; obesity (body mass index  $\ge 30 \text{ kg/m}^2$ ); psychological distress within 30 days before the survey; and comorbidities, which were all self-reported. Household income categories were based on the percentage of family income relative to the federal poverty limit from the U.S. Census Bureau – high income ( $\geq 400\%$ ), middle income ( $\geq 400\%$ ), and low income (<200%). Psychological distress was ascertained with the Kessler-6 Distress Scale score (14). For comorbidities, respondents were asked if they had ever received a clinician diagnosis of arthritis, cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, or failing/weak kidneys. Statistical analysis All statistical analyses incorporated the complex survey design and weighting for selection probabilities and non-response. Variance estimation for the entire pooled cohort was obtained from the Integrated Public Use Microdata Series (https://www.nhis.ipums.org) (15). We assessed

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

the statistical significance of our estimates with a two-tailed alpha significance level of 5%. We used Stata version 16 software (StataCorp, College Station, Texas) for all analyses. We summarized the distribution of individual characteristics – mean (SD) for age; median (IQR) for Kessler 6 score; sample frequency with weighted proportion for discrete variables) in the total population and by ASCVD status. Chi-squared, t-test, and Mann-Whitney u test statistics were used to compare the descriptive statistics between the ASCVD groups for discrete variables, linear age, and Kessler 6 score, respectively. For HALex, we provided age-and-sex adjusted least-square mean scores (with SE) for the total population and by ASCVD status. For our primary multivariable analysis, we evaluated the associations between ASCVD and HALex scores using two-part models (16). All models used accounted for linear age, sex, race/ethnicity, insurance status, household income level, educational attainment, obesity, Kessler 6 score, and the individual comorbidities. For the two-part modeling of HALex scores, we first performed a simple negative linear transformation (X = 1 - U), where U = HALex to move the utility index to a "health-utility decrement" scale with right skewness (16). Next, we fitted a first-part logit model for the likelihood of positive (vs. zero) scores, and an ordinary least squares regression in the second part for the predicted score conditioned on having a positive score. The same set of covariates were used in both models. Finally, a simple reconversion of the estimates and 95% confidence limits (U = 1 - X) was performed to obtain results on the original HALex scale (16). About 86% of participants had complete data on all variables of interest and the highest missingness was 7.5% for household income levels with missingness for other variables ranging from 0.8 to 3.3%. Consequently, we did not impute values for any missing data.

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

In subgroup analyses by age group (18-64 years and  $\geq$  65 years), sex, and race/ethnicity, we repeated the fully adjusted analysis of HALex scores and tested for potential interactions between these characteristics and ASCVD status separately. In a secondary analysis of poor HALex, we used odds ratios (OR, 95% CI) to assess the association between ASCVD and poor HALex in the overall population and in subgroups defined by age, sex, and race/ethnicity. **RESULTS** In our sample of 155,130 NHIS participants with complete HALex data, the estimated prevalence of ASCVD was 6.8%, representing about 15.7 million adults annually (**Table 1**). Individuals with ASCVD were more likely to be men, older, have Medicare insurance plan, and reside in low-income households. They also reported a greater burden of comorbidities. Summary of HALex scores Overall, adults with ASCVD had lower mean HALex scores (0.67 [SE 0.01]) than those without ASCVD (0.87 [SE 0.00]). This trend was observed across all study characteristics (**Table 2**). With ASCVD, females averaged a significantly lower HALex score than males (0.62 vs. 0.69), a contrast to the similar scores observed in the absence of ASCVD. With ASCVD, persons aged 18-64 years averaged a lower HALex score than those aged  $\geq$  65 years. The reverse – higher HALex scores among persons 18-64 years of age – was observed in the absence of ASCVD. Non-Hispanic Blacks averaged the lowest HALex scores, irrespective of ASCVD status. Lower educational status, lower household income and higher psychological distress were all associated

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

with significantly lower HALex scores than the respective counterparts in both ASCVD groups. Of the comorbidities, COPD and kidney failure were associated with the lowest HALex scores reflecting their debilitating nature. Multivariable ASCVD-HALex score analysis We present our multivariable analysis of HALex scores. Overall, ASCVD was associated with a clinically relevant decrease in HALex performance ( $\beta = -0.10$ ; 95% CI [-0.10, -0.09]) (**Figure 1**). We observed, in separate models, significant interactions between ASCVD and sex (p < 0.001), and race/ethnicity (p < 0.001). The decrement in HALex scores associated with ASCVD was greater in females ( $\beta = -0.11, 95\%$  CI [-0.12, -0.10]) than in males ( $\beta = -0.08, 95\%$  CI [-0.09, -0.07]). For age groups, the negative impact of ASCVD on HALex scores was observed to be greater in the younger age group ( $\beta = -0.09, 95\%$  CI [-0.10, -0.08]) than those aged  $\geq 65$  years ( $\beta$ = -0.06, 95% CI [-0.07, -0.06]). For racial/ethnic subgroups, the greatest ASCVD impact was observed with non-Hispanic Blacks ( $\beta = -0.13, 95\%$  CI [-0.15, -0.11]). The decrement in HALex associated with ASCVD was not clinically different between non-Hispanic White ( $\beta = -0.09$ , 95% CI [-0.10, -0.08]) and Hispanics ( $\beta$  = -0.10, 95% CI [-0.12, -0.08]) groups. Secondary analysis of poor HALex Overall, 17.7% (95% CI [17.4, 18.1]) of the study population performed poorly on HALex. A significantly greater proportion in the ASCVD group had poor HALex than those without ASCVD (40.3% v. 15.3%; p < 0.001; **Appendix**). The distribution of poor HALex performance across study variables for the ASCVD groups are presented as well in the Appendix.

From the multivariable analysis, ASCVD was associated with increased odds of poor HALex 2.5 times that observed with the group without ASCVD (OR = 2.46, 95% CI [2.28, 2.66]). Interactions between ASCVD and age group and ASCVD and race/ethnicity were statistically significant (p < 0.001), but there was no significant interaction observed between ASCVD and sex (p = 0.05). The increment in odds of poor HALex associated with ASCVD was higher in age 18-64 years (OR = 2.84; 95% CI [2.52, 3.20]) than in age  $\geq$ 65 years. Similarly, the increment in odds of poor HALex associated with ASCVD was highest in the non-Hispanic Black group (OR = 2.33; 95% CI [2.74, 4.04]). Hispanic and non-Hispanic White groups had similar increments in odds of poor HALex associated with ASCVD presence.

### **DISCUSSION**

In a large survey of adults in the U.S., reporting any ASCVD condition was associated with a significantly lower HRQoL (as measured with HALex). This clinically significant difference was independent of demography, education, insurance, household income, and comorbidity burden. Further, the impact of ASCVD on lower HALex scores was significantly greater in females, adults 18-64 years of age, and non-Hispanic Black adults. The impacts of ASCVD on HALex scores and poor HALex performance were similar in the Hispanic and non-Hispanic White groups. We did not intend to establish clinical values of HALex for persons with ASCVD. Rather, we set out to corroborate the construct validity of a HRQoL tool that could be implemented in the clinical workflow without much challenge.

The sex differences in the impact of ASCVD on HALex is congruent with the established trend that women have poorer health outcomes in conditions like coronary heart disease (17). Women

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

may present as a diagnostic dilemma in the clinic due to confounding atypical presentations or less common pathophysiological processes. Consequently, they are less likely to receive prompt and/or appropriate management to realize optimal outcomes (18,19). We also observed worse HRQoL and the largest ASCVD decrement in non-Hispanic Black compared to the other groups. A similar trend was previously observed in a national survey of adults 35-89 years of age which assessed HRQoL with various indices (20). Interestingly, the impact of ASCVD on HRQoL in Hispanic was comparable to non-Hispanic White, despite the former averaging lower HALex in the presence of ASCVD. This paradox, commonly observed in population studies on other health outcomes (21), could be related to a more resilient subjective construct of health in the face of health challenges owing to cultural values and supportive social relationships among Hispanics (22). On average, we observed lower HALex scores in those 18-64 years of age with ASCVD than their older counterparts. Though not statistically significant, we also observed a greater decrement in HALex with ASCVD in the group 18-64 years of age (-0.09 vs -0.06). While younger age is associated with better health and a greater chance of recovering from ASCVD and its management, younger individuals are more likely to have maladaptive and adverse psychological experiences after their diagnosis (23). Another potential explanation to this observation is the phenomenon that aging populations may report better subjective health due to lowered expectations rather than 'actual' better health (24). *Implications* The adoption into clinical workflow of a HRQoL tool like HALex – which is easy to administer and has construct validity – would be in line with the call to routinely assess PROMs in the

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

clinic. HALex is impacted by the burden of chronic disease, more so than other preference-based measures (25,26). This is in part due to the ability of the constituent perceived-health-status item to discriminate well among levels of functioning (27). As physical functioning is strongly associated with cardiovascular disease prognosis, HALex assessment could be relevant in patient management, especially in the holistic evaluation of rehabilitation (28). Additionally, HALex may have utility in longitudinally assessing the impact of treatment on HRQoL (29). Under a chronic care model with self-management support strategy, patients are reinforced to assume an active and shared responsibility of their health with providers. They are educated to better recognize their health issues, acknowledge the need for health behavior modifications, and initiate and maintain such modifications. In utilizing this context of care, perceived health status (and HALex) would be based on a more comprehensive conceptualization of health standards set and evaluated by patients themselves. Consequently, for patients who may not have a change in physical functioning, a change in their valuation of their own health could signal deficiencies in care standards. Limitations HALex as a HROoL measure is not without limitations. Firstly, domains of health such as emotional, mental, and social functioning, which are relevant in HRQoL (30), are omitted in HALex derivation. This may its discrimination ability, especially for populations with clustering at the highest level of health (5). Nevertheless, we accounted for psychological distress using a valid and reliable tool in the Kessler 6 distress scale, which minimizes the bias from this health domain on our estimates.

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

Secondly, the reliance of HALex on a subjectively perceived health status raises the question of how much of the difference in HALex scores may be related to differential perception. Although perceived health status tends to be congruous with objective measures of health, differences exist between the two health assessments owing to varying health expectations (or preoccupations), and the relevance of physical function to major lifetime occupation (31). Nevertheless, it is well known that the manner in which people account for the many dimensions of health when rating their overall health is relatively stable across disease populations. Finally, while the NHIS is designed to be representative of the US population, the reliance on self-reports for health information including medical conditions and anthropometric measurements (i.e., weight and height) implies some potential for misclassification of study variables. However, previous studies have found a high correlation between the self-reported information in NHIS and the verified information found in other national datasets (32). **CONCLUSION** In conclusion, ASCVD is associated with lower HALex and this association was observed to be greater in female adults, younger age group, and non-Hispanic Black persons. HALex retains a construct validity and has a low administration burden, making it a potentially useful HRQoL tool to implement in healthcare delivery.

#### REFERENCES

287

- 288 1. Kornowski R. Patient-reported outcome measures in cardiovascular disease. Eur Heart J -
- Qual Care Clin Outcomes [Internet]. 2021 Aug 9 [cited 2021 Nov 16];(qcab051). Available
- from: https://doi.org/10.1093/ehjqcco/qcab051
- 291 2. Reuben DB, Tinetti ME. Goal-Oriented Patient Care An Alternative Health Outcomes
- 292 Paradigm. N Engl J Med. 2012 Mar 1;366(9):777–9.
- 293 3. Hostetter M, Klein S. Using Patient-Reported Outcomes to Improve Health Care Quality
- [Internet]. The Commonwealth Fund. [cited 2021 Nov 16]. Available from:
- 295 https://www.commonwealthfund.org/publications/newsletter-article/using-patient-reported-
- 296 outcomes-improve-health-care-quality
- 4. Blumenthal DM, Strom JB, Valsdottir LR, Howard SE, Wagle NW, Ho KKL, et al. Patient-
- 298 Reported Outcomes in Cardiology. Circ Cardiovasc Qual Outcomes. 2018
- 299 Nov;11(11):e004794.
- 5. Erickson P. Evaluation of a population-based measure of quality of life: the Health and
- Activity Limitation Index (HALex). Qual Life Res Int J Qual Life Asp Treat Care Rehabil.
- 302 1998 Feb;7(2):101–14.
- 303 6. Hammerschmidt T, Zeitler HP, Gulich M, Leidl R. A comparison of different strategies to
- 304 collect standard gamble utilities. Med Decis Mak Int J Soc Med Decis Mak. 2004
- 305 Oct;24(5):493–503.
- 7. Lam CLK, Brazier J, McGhee SM. Valuation of the SF-6D Health States Is Feasible,
- 307 Acceptable, Reliable, and Valid in a Chinese Population. Value Health J Int Soc
- 308 Pharmacoeconomics Outcomes Res. 2008 Apr;11(2):295–303.
- 309 8. Abellán Perpiñán JM, Sánchez Martínez FI, Martínez Pérez JE, Méndez I. Lowering the
- 310 'Floor' of the Sf-6d Scoring Algorithm Using a Lottery Equivalent Method. Health Econ.
- 311 2012;21(11):1271–85.
- 312 9. National Center for Health Statistics, NHIS Data, Ouestionnaires and Related
- Documentation [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Nov
- 314 17]. Available from: https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm
- 315 10. Livingston EH, Ko CY. Use of the Health and Activities Limitation Index as a Measure of
- 316 Quality of Life in Obesity. Obes Res. 2002;10(8):824–32.
- 317 11. Asada Y. Assessment of the health of Americans: the average health-related quality of life
- and its inequality across individuals and groups. Popul Health Metr. 2005 Jul 13;3(1):7.
- 319 12. Kachan D, Fleming LE, Christ S, Muennig P, Prado G, Tannenbaum SL, et al. Health Status
- of Older US Workers and Nonworkers, National Health Interview Survey, 1997-2011. Prev
- 321 Chronic Dis. 2015 Sep 24;12:E162.

- 322 13. Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important
- difference established in health-related quality of life instruments? Review of anchors and
- methods. Health Qual Life Outcomes. 2020 May 12;18(1):136.
- 325 14. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, et al. Short
- screening scales to monitor population prevalences and trends in non-specific psychological
- 327 distress. Psychol Med. 2002 Aug;32(6):959–76.
- 328 15. Blewett LA, Drew JAR, King ML, Williams KCW. IPUMS Health Surveys: National Health
- Interview Survey, Version 6.4 [dataset] [Internet]. Minneapolis, MN; 2019. Available from:
- 330 https://doi.org/10.18128/D070.V6.4
- 331 16. Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating
- Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research
- Practices Task Force Report. Value Health. 2016 Sep 1;19(6):704–19.
- 17. Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. Med Nov
- 335 Technol Devices. 2019 Dec 1;4:100025.
- 336 18. Gelber A, Drescher M, Shiber S. Sex Differences in Identifying Chest Pain as Being of
- Cardiac Origin Using the HEART Pathway in the Emergency Department. J Womens Health
- 338 2002. 2022 Jul;31(7):926–31.
- 339 19. Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein ☐ Grobusch K, Hyun K, et al. Sex
- 340 Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic
- Review and Meta Analysis. J Am Heart Assoc. 2020 Jun 2;9(11):e014742.
- 20. Pereira CCA, Palta M, Mullahy J, Fryback DG. Race and preference-based health-related
- quality of life measures in the United States. Qual Life Res Int J Qual Life Asp Treat Care
- 344 Rehabil. 2011 Aug;20(6):969–78.
- 21. Ruiz JM, Steffen P, Smith TB. Hispanic Mortality Paradox: A Systematic Review and Meta-
- Analysis of the Longitudinal Literature. Am J Public Health. 2013 Mar;103(3):e52–60.
- 347 22. Gallo LC, Penedo FJ, Espinosa de los Monteros K, Arguelles W. Resiliency in the Face of
- 348 Disadvantage: Do Hispanic Cultural Characteristics Protect Health Outcomes? J Pers.
- 349 2009;77(6):1707–46.
- 350 23. Okunrintemi V, Benson EMA, Derbal O, Miedema MD, Blumenthal RS, Tibuakuu M, et al.
- Age-specific differences in patient reported outcomes among adults with atherosclerotic
- 352 cardiovascular disease: Medical expenditure panel survey 2006–2015. Am J Prev Cardiol.
- 353 2020 Sep 1;3:100083.
- 24. Sarkisian CA, Prohaska TR, Wong MD, Hirsch S, Mangione CM. The relationship between
- expectations for aging and physical activity among older adults. J Gen Intern Med. 2005
- 356 Oct;20(10):911–5.

- 25. Hanmer J, Cherepanov D, Palta M, Kaplan RM, Feeny D, Fryback DG. Health Condition
- Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by
- Preference-Based Health Index. Med Decis Mak Int J Soc Med Decis Mak. 2016
- 360 Feb;36(2):264–74.
- 361 26. Stewart ST, Cutler DM, Rosen AB. Comparison of trends in US health-related quality of life
- over the 2000s using the SF-6D, HALex, EQ-5D, and EQ-5D visual analog scale versus a
- broader set of symptoms and impairments. Med Care. 2014 Dec;52(12):1010–6.
- 27. Idler EL, Kasl SV. Self-ratings of health: do they also predict change in functional ability? J
- 365 Gerontol B Psychol Sci Soc Sci. 1995 Nov;50(6):S344-353.
- 28. Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review. Int J Nurs Stud. 2012 Jun;49(6):755–71.
- , , ,
- 368 29. Health Services Delivery Programme, Division of Health Systems and Public Health.
- Integrated care models: an overview [Internet]. World Health Organization: Regional Office
- for Europe; 2016 Oct p. 1–31. Available from:
- 371 https://www.euro.who.int/\_\_data/assets/pdf\_file/0005/322475/Integrated-care-models-
- overview.pdf
- 373 30. McDowell I. Measuring Health: A guide to rating scales and questionnaires [Internet]. 3rd
- ed. New York: Oxford University Press; 2006 [cited 2021 Nov 18]. 764 p. Available from:
- https://oxford.universitypressscholarship.com/10.1093/acprof:oso/9780195165678.001.0001/
- 376 acprof-9780195165678
- 377 31. Maddox GL. Some Correlates of Differences in Self-assessment of Health Status Among the
- 378 Elderly1. J Gerontol. 1962 Apr 1;17(2):180–5.
- 379 32. Nelson DE, Powell-Griner E, Town M, Kovar MG. A Comparison of National Estimates
- From the National Health Interview Survey and the Behavioral Risk Factor Surveillance
- 381 System. Am J Public Health. 2003 Aug;93(8):1335–41.

Figure 1. Association between HALex and ASCVD from the National Health Interview Survey 2013-2017.

[Caption] <sup>1</sup> Adjusted for sex, age (linear), race/ethnicity, insurance status, household income level, educational attainment, obesity, Kessler-6 score, and comorbidities.

<sup>2</sup> Adjusted for age (linear), race/ethnicity, insurance status, household income level, educational attainment, obesity, Kessler-6 score, and comorbidities.

<sup>3</sup> Adjusted for sex, race/ethnicity, insurance status, household income level, educational attainment, obesity, Kessler-6 score, and comorbidities.

<sup>4</sup> Adjusted for sex, age (linear), insurance status, household income level, educational attainment, obesity, psychological distress, and comorbidities.

\* Other race/ethnicity group not shown due to limited sample size.

† p-value for the test of interaction with Bonferroni correction.

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

**DECLARATIONS** Ethics approval and consent to participate Not applicable. **Consent for publication** Not applicable. Availability of data and materials The datasets analyzed in the current study are available from the corresponding author on reasonable request. **Competing interests K.N.** is on the advisory board of Amgen and Novartis, and his research is partly supported by the Jerold B. Katz Academy of Translational Research. K.N. and M.CA. are on the Steering Committee of the PAK-SEHAT Study, partially funded by an unrestricted research grant from Getz Pharma. A.A.H. declares current funding from the United States National Institutes of Health, the World Bank, and the World Health Organization. The other authors report no conflicts of interest relevant to this work. **Funding** Not applicable **Authors' contributions** K.K.H., K.N., and Z.J. contributed to the study's conception and design. Material preparation and data analysis were performed by K.K.H. and J.VE. The first draft of the manuscript was prepared by K.K.H. and Z.J. S.L. prepared all figures. All authors reviewed the manuscript. All authors read and approved the final manuscript. Acknowledgements

419 Not applicable.

Table 1. Characteristics of adults  $\geq$  18 years from the National Health Interview Survey (2013-2017).

Characteristic	Total	No ASCVD	ASCVD
Sample	N=155,130	142,866	12,264
Weighted population, n (%)	231,560,617	215,812,388 (93.2)	15,748,229 (6.8)
	Sociodemographic		
Sex*			
Male	73,825 (48.3)	65,607 (47.7)	8,218 (56.9)
Female	90,525 (51.7)	82,985 (52.3)	7,540 (43.1)
Mean age*	49.75 (SD 18.39)	48.04 (SD 17.93)	66.84 (SD 13.63)
Age group*			
18-64 years	121,956 (78.62)	116,295 (81.40)	5,661 (46.16)
≥ 65 years	33,174 (21.38)	26,571 (18.60)	6,603 (53.84)
Race/Ethnicity*			
Non-Hispanic White	100,223 (65.2)	91,521 (64.6)	8,702 (72.8)
Non-Hispanic Black	20,284 (12.1)	18,492 (12.1)	1,792 (12.5)
Non-Hispanic Asian	8,880 (5.9)	8,523 (6.1)	357 (3.2)
Hispanic	23,759 (15.8)	22,529 (16.3)	1,230 (10.3)
Other	1,984 (1.0)	1,801 (1.0)	183 (1.2)
Insurance status*			
Uninsured	18,953 (12.3)	18,277 (12.8)	676 (6.1)
Private	78,944 (56.9)	76,628 (59.3)	2,316 (23.7)
Medicare	29,864 (115.5)	24,124 (13.4)	5,740 (45.2)
Medicaid	17,930 (11.0)	15,513 (10.5)	2,417 (17.7)
Other	7,611 (4.3)	6,613 (4.1)	998 (7.4)
Family income*			
High income	51,472 (40.5)	48,691 (41.3)	2,781 (29.8)
Middle income	40,789 (28.7)	37,619 (28.6)	3,170 (29.9)
Low income	51,546 (30.8)	46,261 (30.1)	5,285 (40.3)
Education*			
≥ College degree	65,124 (42.9)	61,444 (43.8)	3,680 (32.5)
Some college	30,612 (19.7)	28,374 (19.8)	2,238 (18.0)
High school/GED	38,533 (25.0)	34,867 (24.6)	3,666 (30.1)
< High school	20,251 (12.4)	17,648 (11.9)	2,603 (19.4)
	Clinical charac	eteristics	
Median Kessler 6 score*	1 (0-4)	1 (0-4)	2 (0-6)
(psychological stress)		24 422 (42.1)	
Arthritis*	37,510 (21.5)	31,133 (19.4)	6,377 (50.0)
Cancer*	14,195 (8.1)	11,618 (7.2)	2,577 (20.4)

COPD*	5,156 (2.7)	3,327 (1.9)	1,829 (13.6)
Diabetes*	14,910 (8.8)	11,353 (7.3)	3,557 (29.6)
Failing/weak kidneys*	3,172 (1.7)	2,052 (1.2)	1,120 (8.6)
Obesity*	49,863 (31.9)	45,059 (31.3)	4,804 (40.1)
Hypertension*	49,960 (29.1)	40,998 (26.0)	8,962 (71.7)

Column % weighted to the US population presented.

 $Abbreviations: ASCVD-atherosclerotic cardiovascular \ disease. \ COPD-chronic \ obstructive \ pulmonary \ disease. \ GED-general \ educational \ development.$ 

<sup>\*</sup> All tests of comparison by ASCVD status were statistically significant (p < 0.001).

Table 2. Age- and sex-adjusted mean HALex scores of adults  $\geq$  18 years from the National Health Interview Survey (2013-2017).

Characteristics	Total	ASCVD	No ASCVD				
Overall	0.85 (0.00)	0.67 (0.01)	0.87 (0.00)				
Sociodemographic Sociodemographic							
Sex							
Male	0.86 (0.00)	0.69 (0.00)	0.87 (0.00)				
Female	0.84 (0.00)	0.62 (0.01)	0.86 (0.00)				
Age group							
18-64 years	0.85 (0.00)	0.61 (0.01)	0.87 (0.00)				
≥ 65 years	0.81 (0.00)	0.64 (0.01)	0.82 (0.00)				
Race/ethnicity	, ,	, , ,	, ,				
Non-Hispanic White	0.86 (0.00)	0.68 (0.01)	0.87 (0.00)				
Non-Hispanic Black	0.81 (0.00)	0.58 (0.01)	0.83 (0.00)				
Non-Hispanic Asian	0.87 (0.00)	0.71 (0.02)	0.89 (0.00)				
Hispanic	0.83 (0.00)	0.63 (0.01)	0.85 (0.02)				
Other	0.78 (0.01)	0.60 (0.03)	0.80 (0.01)				
Insurance status							
Uninsured	0.82 (0.00)	0.66 (0.01)	0.84 (0.00)				
Private	0.89 (0.00)	0.77 (0.01)	0.90 (0.00)				
Medicare	0.67 (0.00)	0.51 (0.00)	0.68 (0.00)				
Medicaid	0.68 (0.00)	0.49 (0.01)	0.70 (0.00)				
Other	0.81 (0.00)	0.65 (0.01)	0.83 (0.00)				
Education							
≥ College degree	0.89 (0.00)	0.73 (0.01)	0.90 (0.00)				
Some college	0.84 (0.00)	0.67 (0.01)	0.86 (0.00)				
High school/GED	0.82 (0.00)	0.64 (0.01)	0.84 (0.00)				
< High school	0.77 (0.00)	0.58 (0.01)	0.78 (0.00)				
Household income							
High income	0.90 (0.00)	0.78 (0.01)	0.91 (0.00)				
Middle income	0.85 (0.00)	0.70 (0.01)	0.87 (0.00)				
Low income	0.76 (0.00)	0.57 (0.01)	0.79 (0.00)				
	Comorbidi	ties					
Arthritis	0.75 (0.00)	0.57 (0.01)	0.77 (0.00)				
Cancer	0.78 (0.00)	0.60 (0.01)	0.80 (0.00)				
COPD	0.56 (0.01)	0.44 (0.01)	0.60 (0.01)				
Diabetes	0.70 (0.00)	0.53 (0.01)	0.72 (0.00)				
Hypertension	0.78 (0.00)	0.61 (0.01)	0.80 (0.00)				
Kidney failure	0.58 (0.01)	0.45 (0.01)	0.63 (0.01)				
Obesity	0.80 (0.00)	0.62 (0.01)	0.82 (0.00)				
Abbreviations: ASCVD – atherosclerotic cardiovascular disease. COPD – chronic obstructive							
pulmonary disease. GED – general educational development.							

